
Spero Therapeutics SPRO
$ 0.74
-9.76%
Spero Therapeutics ROCE Ratio | SPRO
Annual ROCE Ratio Spero Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.51 | -119.35 | 14.79 | -40.91 | -57.72 | -56.87 | -79.58 | -36.68 | -48.91 | - | -1742.12 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.79 | -1742.12 | -215.68 |
Quarterly ROCE Ratio Spero Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -63.16 | -3.71 | 13.5 | -2.76 | -90.4 | -92.47 | -105.57 | -86.34 | -16.2 | 3.03 | 5.51 | 0.73 | -8.93 | -31.08 | -68.07 | -91.61 | -134.78 | -127.93 | -92.51 | -68.53 | -63.99 | -59.95 | -66.11 | -67.96 | -87.03 | -91.85 | -80.27 | -67.81 | -44.73 | -34.96 | -38.12 | -47.68 | -54.59 | -33.66 | -30.56 | -25.17 | 8.66 | -12.02 | -8.98 | - | 17.42 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.42 | -134.78 | -48.77 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Annexon
ANNX
|
-92.11 | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-17.17 | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
9.07 | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-5.84 | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-68.09 | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
-90.77 | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
-25.89 | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-134.09 | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-46.52 | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-1610.96 | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-106.49 | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-60.71 | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-69.47 | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-235.23 | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-36.31 | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-35.83 | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
-53.23 | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
11.01 | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-141.76 | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-96.98 | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-106.57 | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
458.12 | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
1322.0 | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
166.56 | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
102.23 | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-242.78 | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
-194.9 | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-71.49 | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-59.84 | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
545.12 | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-111.56 | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
-65.26 | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
-101.9 | - | - | $ 127 M | ||
|
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-52.09 | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | ||
|
Gilead Sciences
GILD
|
44.14 | $ 166.01 | -0.31 % | $ 207 B | ||
|
Assembly Biosciences
ASMB
|
-5.8 | $ 22.14 | -1.6 % | $ 248 M | ||
|
Dynavax Technologies Corporation
DVAX
|
-0.69 | - | - | $ 2.02 B | ||
|
Turning Point Therapeutics
TPTX
|
-24.94 | - | -0.13 % | $ 3.73 B | ||
|
Orgenesis
ORGS
|
155.73 | - | -33.86 % | $ 61.2 M | ||
|
TCR2 Therapeutics
TCRR
|
-108.97 | - | - | $ 58.1 M |